DELAWARE
|
22-3367588
|
|
(State
or other jurisdiction of
incorporation or organization) |
(I.R.S.
Employer
Identification Number) |
100
Matawan Road, Suite 420
Matawan,
NJ
|
07747
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
3
|
||||
PART
I. FINANCIAL INFORMATION
|
||||
ITEM
1.
|
FINANCIAL
STATEMENTS
|
|||
4
|
||||
5
|
||||
6
|
||||
7
|
||||
11
|
||||
14
|
||||
PART II. OTHER INFORMATION | ||||
14
|
||||
15
|
||||
15
|
||||
15
|
||||
15
|
||||
15
|
||||
18
|
· |
The
development, testing, and commercialization of new products and the
expansion of the market for our current
products;
|
· |
The
receipt of royalty payments from our agreements with business
partners;
|
· |
Implementing
aspects of our business plans;
|
· |
Financing
goals and plans;
|
· |
Our
existing cash and whether and how long these funds will be sufficient
to
fund our operations; and
|
· |
Our
raising of additional capital through future equity financings.
|
PACIFICHEALTH
LABORATORIES, INC.
|
|||||||
ASSETS
|
|||||||
June
30,
|
December
31,
|
||||||
2007
|
2006
|
||||||
(Unaudited)
|
|
||||||
Current
assets:
|
|||||||
Cash
and cash equivalents
|
$
|
1,500,446
|
$
|
2,564,038
|
|||
Accounts
receivable, net
|
1,170,724
|
502,234
|
|||||
Inventories
|
2,782,219
|
1,913,275
|
|||||
Prepaid
expenses
|
172,155
|
144,059
|
|||||
Total
current assets
|
5,625,544
|
5,123,606
|
|||||
Property
and equipment, net
|
150,405
|
74,163
|
|||||
Deposits
|
10,895
|
10,895
|
|||||
Total
assets
|
$
|
5,786,844
|
$
|
5,208,664
|
|||
LIABILITIES
AND STOCKHOLDERS' EQUITY
|
|||||||
Current
liabilities:
|
|||||||
Notes
payable
|
$
|
78,442
|
$
|
44,327
|
|||
Accounts
payable and accrued expenses
|
986,947
|
960,757
|
|||||
Deferred
revenue
|
332,118
|
244,197
|
|||||
Total
current liabilities
|
1,397,507
|
1,249,281
|
|||||
Stockholders'
equity:
|
|||||||
Common
stock, $.0025 par value; authorized
|
|||||||
50,000,000
shares; issued and outstanding:
|
|||||||
13,352,346
shares at June 30, 2007 and
|
|||||||
12,776,690
shares at December 31, 2006
|
33,381
|
31,942
|
|||||
Additional
paid-in capital
|
18,648,152
|
17,867,945
|
|||||
Accumulated
deficit
|
(14,292,196
|
)
|
(13,940,504
|
)
|
|||
4,389,337
|
3,959,383
|
||||||
Total
liabilities and stockholders' equity
|
$
|
5,786,844
|
$
|
5,208,664
|
|||
See
accompanying notes to financial statements.
|
PACIFICHEALTH
LABORATORIES, INC.
|
|||||||||||||
FOR
THE THREE AND SIX MONTHS ENDED JUNE 30, 2007 AND
2006
|
|||||||||||||
(UNAUDITED)
|
|||||||||||||
Three
Months
|
Six
Months
|
||||||||||||
Ended
June 30,
|
Ended
June 30,
|
||||||||||||
2007
|
2006
|
2007
|
2006
|
||||||||||
Revenues:
|
|||||||||||||
Net
product sales
|
$
|
2,069,889
|
$
|
1,747,206
|
$
|
3,888,783
|
$
|
3,322,602
|
|||||
Cost
of goods sold
|
1,304,359
|
952,691
|
2,437,246
|
1,711,086
|
|||||||||
Gross
profit
|
765,530
|
794,515
|
1,451,537
|
1,611,516
|
|||||||||
|
|||||||||||||
Selling,
general and administrative expenses
|
830,663
|
782,430
|
1,679,829
|
1,530,763
|
|||||||||
Research
and development expenses
|
51,793
|
46,233
|
127,163
|
87,484
|
|||||||||
Depreciation
expense
|
24,519
|
14,858
|
40,331
|
28,952
|
|||||||||
|
906,975
|
843,521
|
1,847,323
|
1,647,199
|
|||||||||
Net
operating loss
|
(141,445
|
)
|
(49,006
|
)
|
(395,786
|
)
|
(35,683
|
)
|
|||||
Other
income (expense):
|
|||||||||||||
Gain
on sale of patents/technology, net of expenses of $90,795
|
-
|
-
|
-
|
3,909,205
|
|||||||||
Other
income
|
-
|
-
|
10,000
|
-
|
|||||||||
Interest
income
|
15,395
|
24,319
|
35,931
|
32,733
|
|||||||||
Interest
expense
|
(1,226
|
)
|
(1,487
|
)
|
(1,837
|
)
|
(30,136
|
)
|
|||||
14,169
|
22,832
|
44,094
|
3,911,802
|
||||||||||
(Loss)
income before income taxes
|
(127,276
|
)
|
(26,174
|
)
|
(351,692
|
)
|
3,876,119
|
||||||
Provision
for income taxes
|
-
|
-
|
-
|
1,278,000
|
|||||||||
Net
(loss) income
|
(127,276
|
)
|
(26,174
|
)
|
(351,692
|
)
|
2,598,119
|
||||||
Less
preferred dividends
|
-
|
(5,000
|
)
|
-
|
(10,425
|
)
|
|||||||
Net
(loss) income applicable to common stockholders
|
$
|
(127,276
|
)
|
$
|
(31,174
|
)
|
$
|
(351,692
|
)
|
$
|
2,587,694
|
||
Basic
(loss) income per share
|
$
|
(0.01
|
)
|
$
|
0.00
|
$
|
(0.03
|
)
|
$
|
0.23
|
|||
|
|
|
|
|
|||||||||
Diluted
(loss) income per share
|
$
|
(0.01
|
)
|
$
|
0.00
|
$
|
(0.03
|
)
|
$
|
0.20
|
|||
Weighted
average common shares - Basic
|
13,319,685
|
11,368,088
|
13,152,745
|
11,070,122
|
|||||||||
Weighted
average common shares - Diluted
|
13,319,685
|
11,368,088
|
13,152,745
|
13,167,853
|
|||||||||
See
accompanying notes to financial statements.
|
PACIFICHEALTH
LABORATORIES, INC.
|
|||||||
FOR
THE SIX MONTHS ENDED JUNE 30, 2007 AND 2006
|
|||||||
(UNAUDITED)
|
|||||||
2007
|
2006
|
||||||
Cash
flows from operating activities:
|
|||||||
Net
(loss) income
|
$
|
(351,692
|
)
|
$
|
2,598,119
|
||
Adjustments
to reconcile net (loss) income to net
|
|||||||
cash
used in operating activities:
|
|||||||
Depreciation
|
40,331
|
28,952
|
|||||
Allowance
for doubtful accounts
|
6,000
|
6,000
|
|||||
Writedown
of packaging inventory
|
49,135
|
-
|
|||||
Equity
instrument based consulting expense
|
124,867
|
109,639
|
|||||
Gain
on sale of patents and technology,
|
|||||||
net
of expenses of $90,795
|
-
|
(3,909,205
|
)
|
||||
Provision
for income taxes
|
-
|
1,278,000
|
|||||
Changes
in operating assets and liabilities:
|
|||||||
Increase
in accounts receivable
|
(674,490
|
)
|
(685,578
|
)
|
|||
(Increase)
decrease in inventories
|
(918,079
|
)
|
163,667
|
||||
Increase
in prepaid expenses
|
(28,096
|
)
|
(58,570
|
)
|
|||
Increase
in deposits
|
-
|
(20,472
|
)
|
||||
Increase
(decrease) in accounts payable/accrued expenses
|
26,190
|
(1,040,432
|
)
|
||||
Increase
(decrease) in deferred revenue
|
87,921
|
(29,835
|
)
|
||||
Net
cash used in operating activities
|
(1,637,913
|
)
|
(1,559,715
|
)
|
|||
Cash
flows from investing activities:
|
|||||||
Purchase
of property and equipment
|
(116,573
|
)
|
(52,145
|
)
|
|||
Proceeds
from sale of patents and technology,
|
|||||||
net
of expenses of $90,795
|
-
|
3,909,205
|
|||||
Net
cash (used in) provided by investing activities
|
(116,573
|
)
|
3,857,060
|
||||
Cash
flows from financing activities:
|
|||||||
Issuance
of notes payable
|
79,305
|
763,443
|
|||||
Repayments
of notes payable
|
(45,190
|
)
|
(825,326
|
)
|
|||
Repayments
of convertible notes payable
|
-
|
(500,000
|
)
|
||||
Common
stock issued
|
450,000
|
-
|
|||||
Proceeds
from common stock options/warrants exercised
|
206,779
|
869,884
|
|||||
Net
cash provided by financing activities
|
690,894
|
308,001
|
|||||
Net
(decrease) increase in cash
|
(1,063,592
|
)
|
2,605,346
|
||||
|
|||||||
Cash,
beginning balance
|
2,564,038
|
138,487
|
|||||
|
|||||||
Cash,
ending balance
|
$
|
1,500,446
|
$
|
2,743,833
|
|||
|
|||||||
Supplemental
disclosures of cash flow information:
|
|||||||
Cash
paid for interest
|
$
|
1,837
|
$
|
30,136
|
|||
Schedule
of non-cash financing activity:
|
|||||||
Conversion
of 90,909 shares of Series A Preferred Stock
|
|||||||
into
909,091 shares of common stock
|
$
|
-
|
$
|
966,387
|
|||
See
accompanying notes to financial statements.
|
|
The
accompanying unaudited financial statements have been prepared
in
accordance with accounting principles generally accepted in the
United
States of America for interim financial information and with the
instructions for Form 10-QSB and Item 310 of Regulation S-B. Accordingly,
they do not include all of the information and footnotes required
by
generally accepted accounting principles for complete financial
statements. In the opinion of management, all adjustments (consisting
of
normal recurring accruals) considered necessary for a fair presentation
have been included. Operating results for the three and six months
ended
June 30, 2007 are not necessarily indicative of the results that
may be
expected for the year ending December 31, 2007. The unaudited financial
statements should be read in conjunction with the financial statements
and
footnotes thereto included in the Company's annual report on Form
10-KSB
for the year ended December 31,
2006.
|
On
February 22, 2006, pursuant to an Asset Purchase Agreement of the
same
date, the Company sold to Mott’s LLP, a division of Cadbury Schweppes
Americas Beverages (“CSAB”) the patents, trademarks, web sites, and other
intellectual property related to its ACCELERADE and ENDUROX sports
nutrition product lines for $4,000,000 in cash and potential future
royalty payments. Simultaneously, the Company entered into a License
Agreement with CSAB giving it the exclusive, royalty free right
to
continue to sell its sports nutrition products in powder, gel and
pill
form. Consequently, the Company will continue to sell its current
sports
nutrition products in the same manner as prior to the sale of the
intellectual property assets.
|
The
Company will receive royalty payments for a finite period following
the
launch of a product using the purchased assets, subject to an annual
limitation on the amount of the royalty. There are no minimum royalties.
CSAB launched a ready-to-drink (“RTD”) product in late June 2007.
|
The
preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America requires
management to make certain estimates and assumptions that affect
the
reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the financial statements
and the
reported amount of revenue and expenses during the reporting period.
Actual results may differ from these estimates. The significant
estimates
and assumptions made by the Company are in the area of revenue
recognition
as it relates to customer returns, inventory obsolescence, allowance
for
doubtful accounts, and valuation allowances for deferred tax assets,
and
valuation of equity instruments issued under Statement of Financial
Accounting Standards ("SFAS") No. 123R, "Share-Based Payment" ("SFAS
123R").
|
Sales
are recognized when all of the following criteria are met: (1)
persuasive
evidence that an arrangement exists; (2) delivery has occurred
or services
have been rendered; (3) the seller’s price to the buyer is fixed and
determinable; and, (4) collectibility is reasonably assured. Sales
are
recorded net of incentives paid to
customers.
|
The
Company has a sales agreement with a significant customer for all
products
sold to this customer whereby all unsold product is subject to
return
provisions. The Company recognizes revenue when this major customer
sells
through its products to its consumers. At June 30, 2007, the Company
has
deferred $332,118 in revenues related to this customer. At December
31,
2006, the Company had deferred $244,197 in revenues related to
this
customer.
|
As
of June 30, 2007 and December 31, 2006, inventories consisted of
the
following:
|
June
30, 2007
|
||||||||
(Unaudited)
|
December
31, 2006
|
|||||||
Raw
materials
|
$
|
367,839
|
$
|
531,995
|
||||
Work
in process
|
-
|
77,771
|
||||||
Packaging
supplies
|
73,172
|
41,378
|
||||||
Finished
goods
|
2,184,435
|
1,165,188
|
||||||
Finished
goods on consignment
|
156,773
|
96,943
|
||||||
$
|
2,782,219
|
$
|
1,913,275
|
Effective
January 1, 2006, the Company adopted SFAS 123R which establishes
standards
for transactions in which an entity exchanges its equity instruments
for
goods or services. SFAS 123R focuses primarily on accounting for
transactions in which an entity obtains employee services in share-based
payment transactions, including issuances of stock options to employees.
Utilizing the Modified Prospective method, the Company recorded
charges of
$64,023 and $123,357, respectively, in the three- and six- months
ended
June 30, 2007, representing the effect on loss from continuing
operations,
loss before income taxes, and net loss. The impact of the adoption
of 123R
was to reduce basic earnings per share by $0.00 and $0.01, respectively,
in the three- and six- months ended June 30, 2007. The Company
recorded
charges of $49,254 and $98,880, respectively in the three- and
six- months
ended June 30, 2006, representing the effect on (loss) income from
continuing operations, (loss) income before income taxes, and net
(loss)
income. The impact of the adoption of 123R was to reduce basic
earnings
per share by $0.00 and $0.01, respectively, in the three- and six-
months
ended June 30, 2006.
|
The
Company granted 6,000 stock options to employees and directors
during the
three months ended June 30, 2007 with an exercise price of $2.05
per
share. These options vest ratably through the second quarter of
2009.
These options were determined to have a total fair value of $10,254.
The
Company granted 26,000 stock options to employees and directors
during the
six months ended June 30, 2007 with exercise prices ranging from
$2.05 to
$2.14 per share. These options were determined to have a total
fair value
of $46,054. Compensation expense recognized during the three months
ended
June 30, 2007 amounted to $64,023. Compensation expense recognized
during
the six months ended June 30, 2007 amounted to $124,867. These
amounts
were charged to operations and added to paid-in capital in accordance
with
SFAS 123R. The Company granted no options to employees and directors
during the three months ended June 30, 2006. The Company granted
508,000
options to employees and directors during the six months ended
June 30,
2006. These options were determined to have a total fair value
of
$230,540. Compensation expense recognized during the three months
ended
June 30, 2006 amounted to $25,302. Compensation expense recognized
during
the six months ended June 30, 2006 amounted to $98,880. These amounts
were
charged to operations and added to paid-in capital in accordance
with SFAS
123R. The total intrinsic value of options exercised during the
three and
six months ended June 30, 2007 was
$0.
|
The
Company granted no stock options to consultants during the three
months
ended June 30, 2007. The Company granted 1,000 stock options to
a
consultant during the six months ended June 30, 2007 that vested
upon
grant with an exercise price of $2.10 per share. These options
were
determined to have a fair value of $1,510 that was charged to operations
and added to paid-in capital in the six month period ended June
30, 2007.
In addition, 1,000 options previously issued to consultants expired
during
the first six months of 2007. The Company granted no stock options
to
consultants during the three months ended June 30, 2006. The Company
granted 89,000 stock options to consultants during the six months
ended
June 30, 2006 that vested upon grant with an exercise price of
$0.20 per
share. These options were determined to have a fair value of $10,759
that
was charged to operations and added to paid-in capital in the six-month
period ended June 30, 2006.
|
A
summary of employee options activity under our plans as of June
30, 2007
and changes during the six-month period then ended is presented
below:
|
Weighted-
|
|||||||||||||
Weighted-
|
Average
|
||||||||||||
Average
|
Remaining
|
Aggregate
|
|||||||||||
Exercise
|
Contractual
|
Intrinsic
|
|||||||||||
Options
|
Shares
|
Price
|
Term
(Years)
|
Value
|
|||||||||
Balance,
January 1, 2007
|
2,011,500
|
$
|
1.12
|
||||||||||
Granted
during the period
|
26,000
|
$
|
2.12
|
||||||||||
Exercised
during the period
|
(17,000
|
)
|
$
|
0.72
|
|||||||||
Expired
during the period
|
(33,000
|
)
|
$
|
3.80
|
|||||||||
Outstanding,
June 30, 2007
|
1,987,500
|
$
|
1.10
|
2.73
|
$
|
2,658,495
|
|||||||
Exercisable,
June 30, 2007
|
1,259,834
|
$
|
1.18
|
1.96
|
$
|
1,627,676
|
The
market value of the Company’s common stock as of June 30, 2007 was $2.37
per share.
|
Weighted-
|
|||||||
Average
|
|||||||
Grant-Date
|
|||||||
Nonvested
Shares
|
Shares
|
Fair
Value
|
|||||
Nonvested,
January 1, 2007
|
942,000
|
$
|
0.81
|
||||
Granted
during the period
|
26,000
|
$
|
2.12
|
||||
Vested
during the period
|
(240,334
|
)
|
$
|
0.52
|
|||
Forfeited
during the period
|
-
|
$
|
-
|
||||
Nonvested,
June 30, 2007
|
727,666
|
$
|
0.95
|
As
of June 30, 2007, the total fair value of non-vested awards amounted
to
$509,820. The weighted average remaining period over which such
options
are expected to be recognized is 1.97
years.
|
The
fair value of each option award during the three months ended June
30,
2007 is estimated on the date of grant using the Black-Scholes
option
valuation model that uses the assumptions noted in the following
table:
|
|
June
30,
2007
|
|
Expected
volatility
|
106-119%
|
|
Weighted-average
volatility
|
113%
|
|
Expected
dividends
|
0.0%
|
|
Expected
term (in years)
|
5
|
|
Risk-free
rate
|
3.35-4.75%
|
The
Company has
approximately $12,398,000 in federal and $671,000 in state net
operating
loss carryovers generated through December 31, 2006 that can be
used to
offset future taxable income in calendar years 2007 through 2026.
The net
operating loss carryovers will expire in the year 2015 through
the year
2026. As of June 30, 2007, the Company has fully reserved for these
net
operating loss carryovers.
|
In
July 2006, the FASB issued FASB Interpretation No. 48, “Accounting for
Uncertainty in Income Taxes” - an interpretation of FASB Statement No. 109
(“FIN 48”), which clarifies the accounting and disclosure for uncertain
tax positions, as defined. FIN 48 seeks to reduce the diversity
in
practice associated with certain aspects of the recognition and
measurement related to accounting for income taxes. The Company
adopted
the provision of FIN 48 effective January 1, 2007. The adoption
of FIN 48
had no material effect on the Company’s results of operations or financial
position.
|
The
Company’s two largest customers accounted for approximately 17% and 17%,
respectively, of net sales for the three months ended June 30,
2007 and
the Company’s two largest customers accounted for approximately 17% and
17%, respectively, of net sales for the three months ended June
30, 2006.
The Company’s two largest customers accounted for approximately 18% and
14%, respectively, of net sales for the six months ended June 30,
2007 and
the Company’s two largest customers accounted for approximately 21% and
18%, respectively, of net sales for the six months ended June 30,
2006. At
June 30, 2007, amounts due from these two customers represented
approximately 31% and 17%, respectively, of accounts receivable.
At
December 31, 2006, amounts due from these two customers represented
approximately 27% and 14%, respectively, of accounts
receivable.
|
Two
suppliers accounted for approximately 70% and 25%, respectively,
of total
inventory purchases for the three months ended June 30, 2007 and
two
suppliers accounted for approximately 74% and 17%, respectively,
of total
inventory purchases for the three months ended June 30, 2006. Two
suppliers accounted for approximately 64% and 20%, respectively,
of total
inventory purchases for the six months ended June 30, 2007 and
two
suppliers accounted for approximately 58% and 30%, respectively,
of total
inventory purchases for the six months ended June 30, 2006. At
June 30,
2007, amounts due to these two vendors represented approximately
57% and
8%, respectively, of accounts payable and accrued expenses. At
December
31, 2006, amounts due to these two vendors represented approximately
3%
and 2%, respectively, of accounts payable and accrued
expenses.
|
Between
July 1, 2007 and August 8, 2007, the Company has issued an additional
97,894 shares of its common stock as a result of the exercise of
options
and warrants, resulting in proceeds of $51,259. Of these shares,
21,418
were issued pursuant to a cashless exercise
feature.
|
Nominee
|
For
|
Against
|
Abstain
|
|
Robert
Portman
|
10,709,593
|
-0-
|
308,787
|
|
Stephen
P. Kuchen
|
10,709,593
|
-0-
|
308,787
|
|
David
Portman
|
10,709,593
|
-0-
|
308,787
|
|
Michael
Cahr
|
10,710,193
|
-0-
|
308,187
|
|
Adam
Mizel
|
10,713,193
|
-0-
|
305,187
|
|
Marc
Particelli
|
10,710,193
|
-0
|
308,187
|
Matter
|
For
|
Against
|
Abstain
|
|
Appointment
of auditors
|
10,987,322
|
25,975
|
5,083
|
Exhibit
Number
|
Description
of Exhibit(1)
|
|
3(i)(a)
|
Certificate
of Incorporation of PacificHealth Laboratories, Inc. and all amendments
thereto (incorporated by reference to Exhibit 3.1 to PacificHealth
Laboratories, Inc.’s Registration Statement on Form SB-2 (Registration No.
333-36379) filed on September 25, 1997)
|
|
3(i)(b)
|
Certificate
of Amendment of Certificate of Incorporation of PacificHealth
Laboratories, Inc. (incorporated by reference to Exhibit 3.3 to
PacificHealth Laboratories, Inc.’s Annual Report on Form 10-KSB filed on
March 31, 2003)
|
|
Exhibit
Number
|
Description
of Exhibit(1)
|
|
3(i)(c)
|
Certificate
of Designations for Series A Preferred Stock (incorporated by reference
to
Exhibit 3.1 to PacificHealth Laboratories, Inc.’s Current Report on Form
8-K filed on January 28, 2005)
|
|
3(i)(d)
|
Certificate
of Designations for Series B Preferred Stock, filed with the Secretary
of
State of the State of Delaware on April 28, 2005 (incorporated by
reference to Exhibit 3(i) to PacificHealth Laboratories, Inc.’s Current
Report on Form 8-K filed May 4, 2005)
|
|
3(ii)
|
Amended
and Restated Bylaws of PacificHealth Laboratories, Inc. (incorporated
by
reference to Exhibit 3.2.1 to PacificHealth Laboratories, Inc.’s Amendment
No. 3 to Registration Statement on Form SB-2/A filed on December
17,
1997)
|
|
4.1
|
Specimen
Common Stock Certificate (incorporated by reference to Exhibit 4.1
to
PacificHealth Laboratories, Inc.’s Amendment No. 3 to Registration
Statement on Form SB-2/A filed on December 17, 1997)
|
|
4.2.1
|
Form
of Securities Purchase Agreement entered into among PacificHealth
Laboratories, Inc. and Certain of the Selling Stockholders dated
August
26, 2003 (incorporated by reference to Exhibit 4.4 to PacificHealth
Laboratories, Inc.’s Registration Statement on Form SB-2 filed on
September 29, 2003)
|
|
4.2.2
|
Form
of Registration Rights Agreement entered into among PacificHealth
Laboratories, Inc. and Certain of the Selling Stockholders dated
August
26, 2003 (incorporated by reference to Exhibit 4.5 to PacificHealth
Laboratories, Inc.’s Registration Statement on Form SB-2 filed on
September 29, 2003)
|
|
4.2.3
|
Form
of Warrant issued to Certain of the Selling Stockholders in connection
with Exhibit 4.2.1 on August 26, 2003 (incorporated by reference
to
Exhibit 4.6 to PacificHealth Laboratories, Inc.’s Registration Statement
on Form SB-2 filed on September 29, 2003)
|
|
4.3
|
Stock
Purchase Agreement dated June 1, 2001, by and between PacificHealth
Laboratories, Inc. and Glaxo Wellcome International B.V. (incorporated
by
reference to Exhibit 4.1 to PacificHealth Laboratories, Inc.’s Current
Report on Form 8-K filed on June 14, 2001)
|
|
4.4.1
|
Series
A Preferred Stock Purchase Agreement dated January 28, 2005, by and
between PacificHealth Laboratories, Inc. and Hormel HealthLabs, LLC
(incorporated by reference to Exhibit 4.3 to PacificHealth Laboratories,
Inc.’s Annual Report on Form 10-KSB filed on April 15,
2005)
|
|
4.4.2
|
Investors’
Rights Agreement dated January 28, 2005, by and between PacificHealth
Laboratories, Inc. and Hormel HealthLabs, LLC (incorporated by reference
to Exhibit 4.4 to PacificHealth Laboratories, Inc.’s Annual Report on Form
10-KSB filed on April 15, 2005)
|
|
4.4.3
|
Right
of First Refusal and Co-Sale Agreement dated January 28, 2005, by
and
between PacificHealth Laboratories, Inc., Robert Portman and Hormel
HealthLabs, LLC (incorporated by reference to Exhibit 4.5 to PacificHealth
Laboratories, Inc.’s Annual Report on Form 10-KSB filed on April 15,
2005)
|
|
4.4.4
|
Certificate
of Designations for Series A Preferred Stock (incorporated by reference
to
Exhibit 3.1 to PacificHealth Laboratories, Inc.’s Current Report on Form
8-K filed on January 28, 2005)
|
|
Exhibit
Number
|
Description
of Exhibit(1)
|
|
4.5
|
Certificate
of Designations for Series B Preferred Stock, filed with the Secretary
of
State of the State of Delaware on April 28, 2005 (incorporated by
reference to Exhibit 3(i) to PacificHealth Laboratories, Inc.’s Current
Report on Form 8-K filed on May 4, 2005)
|
|
4.6.1
|
Securities
Purchase Agreement, dated August 24, 2005 by and between PacificHealth
Laboratories, Inc. and Hormel HealthLabs, LLC (incorporated by reference
to Exhibit 10.1 to PacificHealth Laboratories, Inc.’s Current Report on
Form 8-K filed on August 30, 2005)
|
|
4.6.2
|
Amended
and Restated Investors’ Rights Agreement dated August 24, 2005 between
PacificHealth Laboratories, Inc. and Hormel HealthLabs, LLC and any
additional investor that becomes a party thereto (incorporated by
reference to Exhibit 4.1 to PacificHealth Laboratories, Inc.’s Current
Report on Form 8-K filed on August 30, 2005)
|
|
4.6.3
|
Form
of Secured Convertible Promissory Note issued in connection with
Exhibit
4.6.1 (incorporated by reference to Exhibit 10.2 to PacificHealth
Laboratories, Inc.’s Current Report on Form 8-K filed on August 30,
2005)
|
|
4.6.4
|
Security
Agreement dated August 24, 2005 by and between PacificHealth Laboratories,
Inc. and Hormel HealthLabs, LLC (incorporated by reference to Exhibit
10.3
to PacificHealth Laboratories, Inc.’s Current Report on Form 8-K filed on
August 30, 2005)
|
|
10.1
|
Employment
Extension Agreement between PacificHealth Laboratories, Inc. and
Robert
Portman effective January 1, 2004, executed February 28, 2006
(incorporated by reference to Exhibit 10.6 to PacificHealth Laboratories,
Inc.’s Post-Effective Amendment to Registration Statement on Form SB-2/A
(File No. 333-109197) filed on May 2, 2006)
|
|
10.2.1
|
Asset
Purchase Agreement dated February 22, 2006, by and between PacificHealth
Laboratories, Inc. and Mott’s LLP (redacted, subject to request for
confidential treatment) (incorporated by reference to Exhibit 10.8
to
PacificHealth Laboratories, Inc.’s Annual report on Form 10-KSB filed on
March 31, 2006)
|
|
10.2.2
|
License
Agreement dated February 22, 2006, by and between PacificHealth
Laboratories, Inc. and Mott’s LLP (redacted, subject to request for
confidential treatment) (incorporated by reference to Exhibit 10.9
to
PacificHealth Laboratories, Inc.’s Annual report on Form 10-KSB filed on
March 31, 2006)
|
|
10.2.3
|
Consulting,
License and Noncompetition Agreement dated February 22, 2006, by
and
between PacificHealth Laboratories, Inc., Mott’s LLP and Robert Portman
(redacted, subject to request for confidential treatment) (incorporated
by
reference to Exhibit 10.10 to PacificHealth Laboratories, Inc.’s Annual
report on Form 10-KSB filed on March 31, 2006)
|
|
31.1
|
Rule
13a-14(a) Certification of Chief Executive Officer (filed
herewith)
|
|
31.2
|
Rule
13a-14(a) Certification of Chief Financial Officer (filed
herewith)
|
32
|
Certifications
of Chief Executive Officer and Chief Financial Officer pursuant to
Section
906 of the Sarbanes-Oxley Act of 2002 (filed
herewith)
|
(1)
|
In
the case of incorporation by reference to documents filed by the
Registrant under the Exchange Act, the Registrant’s file number under the
Exchange Act is 000-23495.
|
PACIFICHEALTH LABORATORIES, INC. | ||
|
||
By: | /s/ STEPHEN P. KUCHEN | |
STEPHEN P. KUCHEN |
||
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | ||
Date: August 8, 2007 |
Exhibit
Number
|
Description
of Exhibit(1)
|
|
3(i)(a)
|
Certificate
of Incorporation of PacificHealth Laboratories, Inc. and all amendments
thereto (incorporated by reference to Exhibit 3.1 to PacificHealth
Laboratories, Inc.’s Registration Statement on Form SB-2 (Registration No.
333-36379) filed on September 25, 1997)
|
|
3(i)(b)
|
Certificate
of Amendment of Certificate of Incorporation of PacificHealth
Laboratories, Inc. (incorporated by reference to Exhibit 3.3 to
PacificHealth Laboratories, Inc.’s Annual Report on Form 10-KSB filed on
March 31, 2003)
|
|
3(i)(c)
|
Certificate
of Designations for Series A Preferred Stock (incorporated by reference
to
Exhibit 3.1 to PacificHealth Laboratories, Inc.’s Current Report on Form
8-K filed on January 28, 2005)
|
|
3(i)(d)
|
Certificate
of Designations for Series B Preferred Stock, filed with the Secretary
of
State of the State of Delaware on April 28, 2005 (incorporated by
reference to Exhibit 3(i) to PacificHealth Laboratories, Inc.’s Current
Report on Form 8-K filed May 4, 2005)
|
|
3(ii)
|
Amended
and Restated Bylaws of PacificHealth Laboratories, Inc. (incorporated
by
reference to Exhibit 3.2.1 to PacificHealth Laboratories, Inc.’s Amendment
No. 3 to Registration Statement on Form SB-2/A filed on December
17,
1997)
|
|
4.1
|
Specimen
Common Stock Certificate (incorporated by reference to Exhibit 4.1
to
PacificHealth Laboratories, Inc.’s Amendment No. 3 to Registration
Statement on Form SB-2/A filed on December 17, 1997)
|
|
4.2.1
|
Form
of Securities Purchase Agreement entered into among PacificHealth
Laboratories, Inc. and Certain of the Selling Stockholders dated
August
26, 2003 (incorporated by reference to Exhibit 4.4 to PacificHealth
Laboratories, Inc.’s Registration Statement on Form SB-2 filed on
September 29, 2003)
|
|
4.2.2
|
Form
of Registration Rights Agreement entered into among PacificHealth
Laboratories, Inc. and Certain of the Selling Stockholders dated
August
26, 2003 (incorporated by reference to Exhibit 4.5 to PacificHealth
Laboratories, Inc.’s Registration Statement on Form SB-2 filed on
September 29, 2003)
|
|
4.2.3
|
Form
of Warrant issued to Certain of the Selling Stockholders in connection
with Exhibit 4.2.1 on August 26, 2003 (incorporated by reference
to
Exhibit 4.6 to PacificHealth Laboratories, Inc.’s Registration Statement
on Form SB-2 filed on September 29, 2003)
|
|
4.3
|
Stock
Purchase Agreement dated June 1, 2001, by and between PacificHealth
Laboratories, Inc. and Glaxo Wellcome International B.V. (incorporated
by
reference to Exhibit 4.1 to PacificHealth Laboratories, Inc.’s Current
Report on Form 8-K filed on June 14, 2001)
|
|
4.4.1
|
Series
A Preferred Stock Purchase Agreement dated January 28, 2005, by and
between PacificHealth Laboratories, Inc. and Hormel HealthLabs, LLC
(incorporated by reference to Exhibit 4.3 to PacificHealth Laboratories,
Inc.’s Annual Report on Form 10-KSB filed on April 15,
2005)
|
|
4.4.2
|
Investors’
Rights Agreement dated January 28, 2005, by and between PacificHealth
Laboratories, Inc. and Hormel HealthLabs, LLC (incorporated by reference
to Exhibit 4.4 to PacificHealth Laboratories, Inc.’s Annual Report on Form
10-KSB filed on April 15, 2005)
|
Exhibit
Number
|
Description
of Exhibit(1)
|
|
4.4.3
|
Right
of First Refusal and Co-Sale Agreement dated January 28, 2005, by
and
between PacificHealth Laboratories, Inc., Robert Portman and Hormel
HealthLabs, LLC (incorporated by reference to Exhibit 4.5 to PacificHealth
Laboratories, Inc.’s Annual Report on Form 10-KSB filed on April 15,
2005)
|
|
4.4.4
|
Certificate
of Designations for Series A Preferred Stock (incorporated by reference
to
Exhibit 3.1 to PacificHealth Laboratories, Inc.’s Current Report on Form
8-K filed on January 28, 2005)
|
|
4.5
|
Certificate
of Designations for Series B Preferred Stock, filed with the Secretary
of
State of the State of Delaware on April 28, 2005 (incorporated by
reference to Exhibit 3(i) to PacificHealth Laboratories, Inc.’s Current
Report on Form 8-K filed on May 4, 2005)
|
|
4.6.1
|
Securities
Purchase Agreement, dated August 24, 2005 by and between PacificHealth
Laboratories, Inc. and Hormel HealthLabs, LLC (incorporated by reference
to Exhibit 10.1 to PacificHealth Laboratories, Inc.’s Current Report on
Form 8-K filed on August 30, 2005)
|
|
4.6.2
|
Amended
and Restated Investors’ Rights Agreement dated August 24, 2005 between
PacificHealth Laboratories, Inc. and Hormel HealthLabs, LLC and any
additional investor that becomes a party thereto (incorporated by
reference to Exhibit 4.1 to PacificHealth Laboratories, Inc.’s Current
Report on Form 8-K filed on August 30, 2005)
|
|
4.6.3
|
Form
of Secured Convertible Promissory Note issued in connection with
Exhibit
4.6.1 (incorporated by reference to Exhibit 10.2 to PacificHealth
Laboratories, Inc.’s Current Report on Form 8-K filed on August 30,
2005)
|
|
4.6.4
|
Security
Agreement dated August 24, 2005 by and between PacificHealth Laboratories,
Inc. and Hormel HealthLabs, LLC (incorporated by reference to Exhibit
10.3
to PacificHealth Laboratories, Inc.’s Current Report on Form 8-K filed on
August 30, 2005)
|
|
10.1
|
Employment
Extension Agreement between PacificHealth Laboratories, Inc. and
Robert
Portman effective January 1, 2004, executed February 28, 2006
(incorporated by reference to Exhibit 10.6 to PacificHealth Laboratories,
Inc.’s Post-Effective Amendment to Registration Statement on Form SB-2
(File No. 333-109197) filed on May 2, 2006)
|
|
10.2.1
|
Asset
Purchase Agreement dated February 22, 2006, by and between PacificHealth
Laboratories, Inc. and Mott’s LLP (redacted, subject to request for
confidential treatment) (incorporated by reference to Exhibit 10.8
to
PacificHealth Laboratories, Inc.’s Annual report on Form 10-KSB filed on
March 31, 2006)
|
|
10.2.2
|
License
Agreement dated February 22, 2006, by and between PacificHealth
Laboratories, Inc. and Mott’s LLP (redacted, subject to request for
confidential treatment) (incorporated by reference to Exhibit 10.9
to
PacificHealth Laboratories, Inc.’s Annual report on Form 10-KSB filed on
March 31, 2006)
|
|
10.2.3
|
Consulting,
License and Noncompetition Agreement dated February 22, 2006, by
and
between PacificHealth Laboratories, Inc., Mott’s LLP and Robert Portman
(redacted, subject to request for confidential treatment) (incorporated
by
reference to Exhibit 10.10 to PacificHealth Laboratories, Inc.’s Annual
report on Form 10-KSB filed on March 31, 2006)
|
|
31.1
|
Rule
13a-14(a) Certification of Chief Executive Officer (filed
herewith)
|
|
31.2
|
Rule
13a-14(a) Certification of Chief Financial Officer (filed
herewith)
|
Exhibit
Number
|
Description
of Exhibit(1)
|
|
32
|
Certifications
of Chief Executive Officer and Chief Financial Officer pursuant
to Section
906 of the Sarbanes-Oxley Act of 2002 (filed
herewith)
|
(1)
|
In
the case of incorporation by reference to documents filed by the
Registrant under the Exchange Act, the Registrant’s file number under the
Exchange Act is 000-23495.
|